NAT2 polymorphisms with oral carcinoma susceptibility: A meta-analysis

Molecular Biology Reports

Volumn 39, Issue 9, 2012, Pages 8813-8819

  Zhuo, Xian Lu ^a,b   Ling, Jun Jun ^a   Zhou, Yan ^a   Zhao, Hou Yu ^b   Song, Yu Feng ^a,b   Tan, Ying Hui ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; NAT2; Oral carcinoma; Polymorphism; Susceptibility

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNIC GROUP; FEMALE; GENE ACTIVITY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MOUTH CARCINOMA; NAT2 GENE; ONCOGENE; RISK ASSESSMENT;

ARYLAMINE N-ACETYLTRANSFERASE; CARCINOMA; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOUTH NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS;

EID: 84865116117     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-1744-3     Document Type: Article

References (35)

1. Zygogianni AG, Kyrgias G, Karakitsos P, Psyrri A, Kouvaris J et al (2011) Oral squamous cell cancer: early detection and the role of alcohol and smoking. Head Neck Oncol 3:2
2. Reichart PA, Nguyen XH (2008) Betel quid chewing, oral cancer and other oral mucosal diseases in Vietnam: a review. J Oral Pathol Med 37:511-514
3. Boffetta P (2010) Biomarkers in cancer epidemiology: an integrative approach. Carcinogenesis 31:121-126
4. Klaunig JE, Kamendulis LM, Hocevar BA (2010) Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 38:96-109
5. Zhuo WL, Zhang YS, Wang Y, Zhuo XL, Zhu B et al (2009) Association studies of CYP1A1 and GSTM1 polymorphisms with esophageal cancer risk: evidence-based meta-analyses. Arch Med Res 40:169-179
6. Liu L, Wagner CR, Hanna PE (2009) Isoform-selective inactivation of human arylamine N-acetyltransferases by reactive metabolites of carcinogenic arylamines. Chem Res Toxicol 22:1962-1974
7. Garcia-Martin E (2008) Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab 9:487-497 (Pubitemid 352034203)
8. Agundez JA (2008) Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab 9:520-531 (Pubitemid 352025183)
9. Luck H, Kinzig M, Jetter A, Fuhr U, Sorgel F (2009) Mesalazine pharmacokinetics and NAT2 phenotype. Eur J Clin Pharmacol 65:47-54
10. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES (2011) Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS One 6:e18507
11. Munafo MR, Clark TG, Flint J (2004) Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res 129:39-44 (Pubitemid 39574435)
12. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315:629-634 (Pubitemid 27387172)
13. Hou YY, Ou HL, Chu ST, Wu PC, Lu PJ et al (2011) NAT2 slow acetylation haplotypes are associated with the increased risk of betel quid-related oral and pharyngeal squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:484-492
14. Jourenkova-Mironova N, Wikman H, Bouchardy C, Mitrunen K, Dayer P et al (1999) Role of arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2) genotypes in susceptibility to oral/pharyngeal and laryngeal cancers. Pharmacogenetics 9:533-537 (Pubitemid 29419573)
15. Morita S, Yano M, Tsujinaka T, Akiyama Y, Taniguchi M et al (1999) Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int J Cancer 80:685-688 (Pubitemid 29066278)
16. Buch SC, Nazar-Stewart V, Weissfeld JL, Romkes M (2008) Case-control study of oral and oropharyngeal cancer in whites and genetic variation in eight metabolic enzymes. Head Neck 30:1139-1147
17. Chen C, Ricks S, Doody DR, Fitzgibbons ED, Porter PL et al (2001) N-acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk. Carcinogenesis 22:1993-1999 (Pubitemid 34065394)
18. Hahn M, Hagedorn G, Kuhlisch E, Schackert HK, Eckelt U (2002) Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer. Oral Oncol 38:486-490 (Pubitemid 34756735)
19. Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K et al (1998) A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis 19:1803-1807 (Pubitemid 28474645)
20. Majumder M, Sikdar N, Ghosh S, Roy B (2007) Polymorphisms at XPD and XRCC1 DNA repair loci and increased risk of oral leukoplakia and cancer among NAT2 slow acetylators. Int J Cancer 120:2148-2156 (Pubitemid 46555851)
21. Marques CF, Koifman S, Koifman RJ, Boffetta P, Brennan P et al (2006) Influence of CYP1A1, CYP2E1, GSTM3 and NAT2 genetic polymorphisms in oral cancer susceptibility: results from a case-control study in Rio de Janeiro. Oral Oncol 42:632-637 (Pubitemid 44173019)
22. Balaji L, Krishna BS, L VKSB (2011) An unlikely role for the NAT2 genotypes and haplotypes in the oral cancer of South Indians. Arch Oral Biol. doi: 10.1016/j.archoralbio.2011.10.019
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Br Med J 327:557-560 (Pubitemid 37088507)
24. Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Techn Bull 8:15-17
25. Gong C, Hu X, Gao Y, Cao Y, Gao F et al (2011) A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review. Med Oncol 28:365-376
26. Ying XJ, Dong P, Shen B, Wang J, Wang S et al (2011) Possible association of NAT2 polymorphism with laryngeal cancer risk: an evidence-based meta-analysis. J Cancer Res Clin Oncol 137:1661-1667
27. Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M et al (2005) NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366:649-659 (Pubitemid 41176017)
28. Moore LE, Baris DR, Figueroa JD, Garcia-Closas M, Karagas MR et al (2011) GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis. Carcinogenesis 32:182-189
29. Ochs-Balcom HM, Wiesner G, Elston RC (2007) A meta-analysis of the association of N-acetyltransferase 2 gene (NAT2) variants with breast cancer. Am J Epidemiol 166:246-254 (Pubitemid 47216806)
30. Zhang J, Qiu LX, Wang ZH, Wang JL, He SS et al (2010) NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 123:877-883
31. Cui D, Wang Z, Zhao E, Ma J, Lu W (2011) NAT2 polymorphism and lung cancer risk: a meta-analysis. Lung Cancer 73:153-157
32. Zhong X, Hui C, Xiao-Ling W, Yan L, Na L (2010) NAT2 polymorphism and gastric cancer susceptibility: a meta-analysis. Arch Med Res 41:275-280
33. Brockton N, Little J, Sharp L, Cotton SC (2000) N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 151:846-861 (Pubitemid 30461126)
34. Walker K, Ginsberg G, Hattis D, Johns DO, Guyton KZ et al (2009) Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health B Crit Rev 12:440-472
35. de Lima KW, Guembarovski RL, Oda JM, Ramos G, Oliveira BV et al (2011) Association between the STin2 VNTR polymorphism and smoking behavior in oral cancer patients and healthy individuals. Clin Exp Med. doi: 10.1007/s10238-011- 0140-y